𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II Randomized Trial of Weekly Paclitaxel with or Without Estramustine Phosphate in Progressive, Metastatic, Hormone-Refractory Prostate Cancer

✍ Scribed by Berry, William R.; Hathorn, James W.; Dakhil, Shaker R.; Loesch, David M.; Jackson, Don V.; Gregurich, Mary Ann; Newcomb-Fernandez, Jennifer K.; Asmar, Lina

Book ID
119935346
Publisher
CIG Media Group, LP.
Year
2004
Tongue
English
Weight
140 KB
Volume
3
Category
Article
ISSN
1540-0352

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Weekly paclitaxel, estramustine phosphat
Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma : Results of a Minnie Pearl Cancer Research Network Phase II Trial
✍ Anthony A. Meluch; F. Anthony Greco; Lisa H. Morrissey; Eric L. Raefsky; Ronald πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 87 KB πŸ‘ 2 views

## Abstract ## BACKGROUND The objective of the current study was to evaluate the efficacy and toxicity of weekly paclitaxel, oral etoposide, and estramustine phosphate in the treatment of patients with advanced, hormone‐refractory prostate carcinoma. ## METHODS Patients with hormone‐refractory p

Phase II trial of paclitaxel, estramusti
Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma
✍ David C. Smith; Christopher H. Chay; Rodney L. Dunn; Jude Fardig; Peg Esper; Kar πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 127 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Preclinical data suggest that the combination of intravenous (i.v.) paclitaxel, carboplatin, oral etoposide, and oral estramustine (TEEC) has significant activity in patients with advanced, hormone‐refractory prostate carcinoma. The authors conducted this clinical trial t